Abstract
Imiquimod, an immune response modifier approved for the treatment of external genital warts, actinic keratoses, and superficial basal cell carcinoma, can induce a severe local inflammatory response. This phenomenon can accompany inappropriately overzealous, as well as entirely conventional, drug utilization. Despite strikingly brisk reactions, the 9 patients reported herein ultimately experienced excellent cosmetic and clinical outcomes. We report this series to alert clinicians of the good prognosis for a satisfactory outcome even when faced with extreme imiquimod cream-induced inflammation.
MeSH terms
-
Adjuvants, Immunologic / administration & dosage
-
Adjuvants, Immunologic / adverse effects
-
Adjuvants, Immunologic / chemistry
-
Administration, Topical
-
Adult
-
Aged
-
Aged, 80 and over
-
Aminoquinolines / administration & dosage
-
Aminoquinolines / adverse effects*
-
Aminoquinolines / chemistry
-
Cheilitis / chemically induced
-
Cheilitis / drug therapy
-
Drug Eruptions / drug therapy
-
Drug Eruptions / etiology*
-
Female
-
Humans
-
Imiquimod
-
Keratosis / chemically induced
-
Keratosis / drug therapy
-
Male
-
Middle Aged
-
Ointments
-
Time Factors
-
Treatment Outcome
Substances
-
Adjuvants, Immunologic
-
Aminoquinolines
-
Ointments
-
Imiquimod